Active Biotech AB - Product Pipeline Review - 2012 - This pharmaceuticals report, "Active Biotech AB - Product Pipeline Review - 2012" provides data on the Active Biotech AB's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from our proprietary databases, Active Biotech AB's corporate website, SEC filings, investor presentations and featured press releases, both from Active Biotech AB and industry-specific third party sources, put together by This team.
Scope
- Active Biotech AB - Brief Active Biotech AB overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Active Biotech AB human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Active Biotech AB with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Active Biotech AB's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Active Biotech AB's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Active Biotech AB in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Active Biotech AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Active Biotech AB.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Active Biotech AB and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of Active Biotech AB; Active Biotech AB - Key Therapeutics; Active Biotech AB - Pipeline Overview and Promising Molecules; Active Biotech AB - News; Active Biotech AB - Latest Updates; Active Biotech AB - Pipeline; Active Biotech AB - Discontinued/Dormant Projects
Table of Contents
Table of Contents
List of Tables
List of Figures
Active Biotech AB Snapshot
Active Biotech AB Overview
Key Information
Key Facts
Active Biotech AB - Research and Development Overview
Key Therapeutic Areas
Active Biotech AB - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Active Biotech AB - Pipeline Products Glance
Active Biotech AB - Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Active Biotech AB Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Active Biotech AB - Early Stage Pipeline Products
Discovery Products/Combination Treatment Modalities
Active Biotech AB - Drug Profiles
57-57
Product Description
Mechanism of Action
R&D Progress
ANYARA
Product Description
Mechanism of Action
R&D Progress
ANYARA + Interferon Alpha
Product Description
Mechanism of Action
R&D Progress
ISI
Product Description
Mechanism of Action
R&D Progress
TASQ
Product Description
Mechanism of Action
R&D Progress
Active Biotech AB - Pipeline Products by Route of Administration
Active Biotech AB - Pipeline Products By Mechanism of Action
Active Biotech AB - Recent Pipeline Updates
Active Biotech AB - Dormant Projects
Active Biotech AB - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
ABR-224050
Active Biotech AB - Company Statement
Active Biotech AB - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Active Biotech AB, Recent Developments
Active Biotech AB- Press Release
Jun 04, 2012: Active Biotech And Ipsen Present Data From Phase II Study Of Tasquinimod At ASCO Annual Meeting
May 21, 2012: Active Biotech And Ipsen Provide Update On Patient Recruitment In Phase III Study Of Tasquinimod
May 18, 2012: Active Biotech And Ipsen To Present Tasquinimod Phase II Overall Survival Data At ASCO 2012 Annual Meeting
Feb 24, 2012: Active Biotech And Ipsen Report Tasquinimod Phase II Long Term Safety Data At 27th European Association Of Urology Congress
Jan 23, 2012: Active Biotech Announces New Phase I Combination Study Under Prostate Cancer Project TASQ
Sep 25, 2009: Active Biotech's Prostate Cancer Project TASQ Features In British Journal Of Cancer
Jul 28, 2009: Active Biotech's Cancer Project ANYARA Features In Journal Of Clinical Oncology
Jun 11, 2009: Active Biotech Presents Data regarding The 57-57 SLE Project At EULAR
Jun 08, 2009: Active Biotech Completes Patient Enrollment To TASQ Clinical Phase II study
Jun 01, 2009: Active Biotech Completes Patient Enrollment To ANYARA Phase III Clinical Trial
Jun 01, 2009: Active Biotech Completes Patient Enrollment To ANYARA Phase III Clinical Trial
Apr 28, 2009: Active Biotech Presents S100A9 As A Target For Quinoline Compounds
Financial Deals Landscape
Active Biotech AB, Deals Summary
Active Biotech AB, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Teva Pharma Industries Amends Licensing Agreement With Active Biotech
Evotec Extends Co-Development Agreement With Active Biotech
Evotec Enters Into An Agreement With Active Biotech
Active Biotech Enters Into Co-Development Agreement With Ipsen
Active Biotech Enters Into Research Agreement With AcureOmics
Active Biotech Enters Into Co-Development Agreement With Chelsea Therapeutics
Equity Offering
Active Biotech Completes Private Placement Of $57 Million
Active Biotech Completes Private Placement Of $20.63 Million
Active Biotech Completes Rights Issue For $33.4 Million
Active Biotech Completes Rights Issue Of $26.49 Million
Active Biotech Completes Rights Offering Of $34.75 Million
Active Biotech Completes Rights Offering Of $0.06 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Active Biotech AB, Key Information
Active Biotech AB, Key Facts
Active Biotech AB - Pipeline by Indication, 2012
Active Biotech AB - Pipeline by Stage of Development, 2012
Active Biotech AB - Monotherapy Products in Pipeline, 2012
Active Biotech AB - Combination Treatment Modalities in Pipeline, 2012
Active Biotech AB - Phase III, 2012
Active Biotech AB - Phase II, 2012
Active Biotech AB - Discovery, 2012
Active Biotech AB - Pipeline By Route of Administration, 2012
Active Biotech AB - Pipeline Products By Mechanism of Action, 2012
Active Biotech AB - Recent Pipeline Updates, 2012
Active Biotech AB - Dormant Developmental Projects,2012
Active Biotech AB - Discontinued Pipeline Products, 2012
Active Biotech AB, Subsidiaries
Active Biotech AB, Deals Summary
Teva Pharma Industries Amends Licensing Agreement With Active Biotech
Evotec Extends Co-Development Agreement With Active Biotech
Evotec Enters Into An Agreement With Active Biotech
Active Biotech Enters Into Co-Development Agreement With Ipsen
Active Biotech Enters Into Research Agreement With AcureOmics
Active Biotech Enters Into Co-Development Agreement With Chelsea Therapeutics
Active Biotech Completes Private Placement Of $57 Million
Active Biotech Completes Private Placement Of $20.63 Million
Active Biotech Completes Rights Issue For $33.4 Million
Active Biotech Completes Rights Issue Of $26.49 Million
Active Biotech Completes Rights Offering Of $34.75 Million
Active Biotech Completes Rights Offering Of $0.06 Million
List of Figures
Active Biotech AB - Pipeline by Indication, 2012
Active Biotech AB - Pipeline by Stage of Development, 2012
Active Biotech AB - Monotherapy Products in Pipeline, 2012
Active Biotech AB - Combination Treatment Modalities in Pipeline, 2012
Active Biotech AB - Pipeline By Route of Administration, 2012
Active Biotech AB - Pipeline Products By Mechanism of Action, 2012 23
